CTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
CTI BioPharma Corp. (NASDAQ: CTIC) will present a corporate overview at the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CTI BioPharma Corp. (NASDAQ: CTIC) will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2023, at 7:30 a.m. PT (10:30 a.m. ET). The presentation will be available for live webcast and replay on CTI's website. The company specializes in targeted therapies for blood-related cancers, with an FDA-approved product, VONJO®, for treating myelofibrosis in certain patients. Continued approval may depend on clinical benefit verification through ongoing studies.
Details
News Market Reaction – CTIC
The recorded move for CTIC in the trading session of this news was -0.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Jan. 5, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.
Presentation details:
Event: 41st Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 12, 2023
Time: 7:30 a.m. PT/10:30 a.m. ET
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.
About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO® (pacritinib), a JAK2 and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO® is a registered trademark of CTI BioPharma Corp.
CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301713528.html
SOURCE CTI BioPharma Corp.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.